Integrin linked kinase modulation of monocyte activation
US7504228B2 · kind B2 · utility
0Cited by
8References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 5, 2002 |
| Grant date | Mar 17, 2009 |
| Priority date | — |
| Expiry date | Oct 22, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided to specifically modulate the activation of monocytes and/or macrophages. Administration of integrin linked kinase (ILK) blocking agents; compounds that otherwise prevent the binding of natural ILK ligands to ILK; or compounds that prevent expression of, or signaling through ILK exert an anti-inflammatory effect by inhibiting iNOS and COX-2 expression, at the level of transcription by suppressing the activation of NF-κB. The modulation of activation through ILK is used to regulate immune processes at targeted sites, for example to decrease undesirable inflammatory responses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.